Biotechs explore the next generation of inflammasome targets, with caution

As the NLRP3 field gains momentum, drawing VC and pharma interest for the role the target plays in diseases ranging from NASH to neurodegeneration, biotechs are beginning to eye the next crop of inflammasome targets.

At least two companies -- IFM Therapeutics LLC and ZyVersa Therapeutics Inc. -- are diving in with preclinical programs against novel inflammasome targets, while others are waiting to see the first clinical data from NLRP3 programs before committing to their choice of target...